Form 4: Replimune Director Kapil Dhingra Granted 44,500 Options

Replimune Group, Inc. director Kapil Dhingra received a grant of 44,500 stock options with an exercise price of $7.61, set to vest in 2027.

Summary

• Kapil Dhingra, a member of the Board of Directors, was granted 44,500 stock options on April 1, 2026.
• The options carry an exercise price of $7.61 per share.
• The grant is scheduled to vest in full on April 1, 2027, provided the director remains with the company.
• The options have a ten-year term, expiring on April 1, 2036.
• The filing was submitted to the SEC on April 7, 2026, which was noted as a late filing due to administrative error.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event; while it shows insider alignment, the late filing is a minor negative for corporate governance optics.

Positives

• Aligns director interests with those of shareholders through equity-based compensation.
• The exercise price of $7.61 establishes a baseline for future stock price appreciation goals.
• Long-term commitment indicated by a 10-year expiration date on the options.

Negatives

• The filing was submitted late, which may indicate minor administrative or compliance oversights within the company's reporting processes.

Risks

• Potential for future share dilution if the options are exercised.
• The options only provide value to the holder if the market price of the stock exceeds $7.61 after the vesting date.

Future Outlook

The grant of these options suggests that the company continues to use equity as a primary tool for director retention and incentive, with a focus on performance over the next twelve months leading up to the vesting date.

Management Comments

• This Form 4 is being filed late due to inadvertent administrative error.

Industry Context

StockSavvy.ai notes that equity-heavy compensation for directors is standard in the biotechnology sector, particularly for clinical-stage companies, to preserve cash while incentivizing long-term value creation.

Comparison to Industry Standards

• The grant of 44,500 options is consistent with annual director compensation packages seen at other mid-cap biotech firms such as Iovance Biotherapeutics or Rocket Pharmaceuticals.
• A one-year cliff vesting schedule is a common industry standard for non-employee director equity grants.

Corporate Governance

Related Party Transactions

• The issuance of derivative securities to a director of the company as part of a compensation arrangement.

Stakeholder Impact

• Shareholders may experience a minor dilutive effect upon the future exercise of these options.
• Director Kapil Dhingra gains a significant potential stake in the company's future equity growth.

Next Steps

• Full vesting of the options on April 1, 2027.

Key Dates

Recommendation

This is a routine administrative filing regarding director compensation and does not signal a change in the company's fundamental value or strategic direction.

Keywords

Replimune Group, REPL, Insider Trading, Stock Options, Kapil Dhingra, Director Compensation, Biotechnology, SEC Form 4